Insights into recent findings and clinical application of YAP and TAZ in cancer
Decades of research have mapped out the basic mechanics of the Hippo pathway. The
paralogues Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding …
paralogues Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding …
Therapeutic targeting of TEAD transcription factors in cancer
The Hippo signaling pathway inhibits the activity of the oncogenic YAP (Yes-associated
protein)/TAZ (transcriptional co-activator with PDZ-binding motif)–TEAD (TEA/ATTS domain) …
protein)/TAZ (transcriptional co-activator with PDZ-binding motif)–TEAD (TEA/ATTS domain) …
New insights into the ambivalent role of YAP/TAZ in human cancers
J Luo, L Deng, H Zou, Y Guo, T Tong, M Huang… - Journal of Experimental …, 2023 - Springer
Hippo signaling was first identified in Drosophila as a key controller of organ size by
regulating cell proliferation and anti-apoptosis. Subsequent studies have shown that this …
regulating cell proliferation and anti-apoptosis. Subsequent studies have shown that this …
The oncogenic roles and clinical implications of YAP/TAZ in breast cancer
J Luo, H Zou, Y Guo, T Tong, Y Chen, Y Xiao… - British Journal of …, 2023 - nature.com
Breast cancer (BC) is the most commonly diagnosed form of cancer and a leading cause of
cancer-related deaths among women worldwide. Yes-associated protein (YAP) and …
cancer-related deaths among women worldwide. Yes-associated protein (YAP) and …
New insights into YAP/TAZ-TEAD-mediated gene regulation and biological processes in cancer
Simple Summary The Hippo pathway is crucial for regulating cell growth, organ size, and
tissue regeneration. When this pathway goes awry, it can lead to uncontrolled cell growth …
tissue regeneration. When this pathway goes awry, it can lead to uncontrolled cell growth …
circRNA-SFMBT2 orchestrates ERα activation to drive tamoxifen resistance in breast cancer cells
Z Li, Y Li, D Han, X Wang, C Li, T Chen, W Li… - Cell death & …, 2023 - nature.com
Dysregulated ERα signaling is responsible for endocrine resistance and eventual relapse in
patients with estrogen receptor-positive (ER+) breast cancer. Thus, identifying novel ERα …
patients with estrogen receptor-positive (ER+) breast cancer. Thus, identifying novel ERα …
YAP antagonizes TEAD‐mediated AR signaling and prostate cancer growth
Hippo signaling restricts tumor growth by inhibiting the oncogenic potential of YAP/TAZ‐
TEAD transcriptional complex. Here, we uncover a context‐dependent tumor suppressor …
TEAD transcriptional complex. Here, we uncover a context‐dependent tumor suppressor …
YAP represses the TEAD–NF-κB complex and inhibits the growth of clear cell renal cell carcinoma
Z Li, P Su, M Yu, X Zhang, Y Xu, T Jia, P Yang… - Science …, 2024 - science.org
The Hippo pathway is generally understood to inhibit tumor growth by phosphorylating the
transcriptional cofactor YAP to sequester it to the cytoplasm and reduce the formation of YAP …
transcriptional cofactor YAP to sequester it to the cytoplasm and reduce the formation of YAP …
Matrix stiffness affects tumor-associated macrophage functional polarization and its potential in tumor therapy
J Xiong, R Xiao, J Zhao, Q Zhao, M Luo, F Li… - Journal of Translational …, 2024 - Springer
The extracellular matrix (ECM) plays critical roles in cytoskeletal support, biomechanical
transduction and biochemical signal transformation. Tumor-associated macrophage (TAM) …
transduction and biochemical signal transformation. Tumor-associated macrophage (TAM) …
[HTML][HTML] Comparative analysis of YAP/TEAD inhibitors in 2D and 3D cultures of primary human hepatocytes reveals a novel non-canonical mechanism of CYP …
N Oliva-Vilarnau, SU Vorrink, FA Büttner… - Biochemical …, 2023 - Elsevier
Induction of cytochrome P450 (CYP) genes constitutes an important cause of drug–drug
interactions and preclinical evaluation of induction liability is mandatory for novel drug …
interactions and preclinical evaluation of induction liability is mandatory for novel drug …